Key Details
Price
$2.74Annual ROE
-70.01%Beta
0.39Events Calendar
Next earnings date:
Mar 6, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 6, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Apr 27, 2021Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE: ABT) in April 2023.
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.15 per share a year ago.
MIAMI, Nov. 08, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to five new non-executive employees in the aggregate amount of 197,167 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of October 24, 2024, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
MIAMI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headquarters in Miami, Florida. The new facility will ideally position the Company to support the anticipated U.S. launch and commercialization of the CGuard Prime carotid stent system in the first half of 2025, if approved.
InspireMD announces the submission of the PMA application to the FDA for marketing approval of the CGuard Prime EPS.
PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May
- Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial –
CGuard was the only investigational carotid stent approved by FDA for inclusion in the trials CREST-2 included 23 cases implanted with CGuard TEL AVIV, Israel and MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today congratulated the lead investigators on the completion of enrollment in the CREST-2 (Carotid Revascularization Endarterectomy or Stenting Trial) clinical trials. The CGuard carotid stent, utilizing its proprietary MicroNet™ mesh, was included as a device option for stenting in the CREST-2 trials following FDA approval of InspireMD's Investigational Device Exemption (IDE) supplement application in February 2022.
FAQ
- What is the ticker symbol for InspireMD?
- Does InspireMD pay dividends?
- What sector is InspireMD in?
- What industry is InspireMD in?
- What country is InspireMD based in?
- When did InspireMD go public?
- Is InspireMD in the S&P 500?
- Is InspireMD in the NASDAQ 100?
- Is InspireMD in the Dow Jones?
- When was InspireMD's last earnings report?
- When does InspireMD report earnings?
- Should I buy InspireMD stock now?